Abstract
We performed a single-institution phase II study to evaluate the efficacy and toxicities of vinorelbine monotherapy in patients previously treated with anthracyclines and taxanes. Vinorelbine was administered at a dose level of 25 mg/m² intravenously on days 1, 8, 15 and 22, every four weeks, and responses were assessed after every two cycles of treatment. All of the patients had previously been treated with anthracyclines and taxanes. A total of 26 patients were enrolled in this study between April 2004 and August 2009. The median age of the patients was 47 years (range, 37 to 71 years), and 80.8% had an Eastern Cooperative Oncology Group performance status of 0 or 1. Out of 24 evaluable patients, five partial responses were observed, giving an overall response rate of 20.8%, with a median response duration of 2.8 months. The median time to progression was 3.7 months (range, 0.5 to 22.6 months), and median overall survival duration was 10.4 months (range, 1.3 to 57.6 months). The major toxicities observed were neutropenia, anemia and peripheral neuropathy. Grade 3 or 4 hematologic toxicities included neutropenia in 18 patients (69.2%) and anemia in four patients (15.3%). Grade 1 or 2 peripheral neuropathy was observed in 11 pa...Continue Reading
References
Oct 1, 1995·American Journal of Clinical Oncology·S BrunoG Kesselring
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L WeberJ Hohneker
Nov 1, 1994·British Journal of Cancer·C J TwelvesR D Rubens
May 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DegardinA Demaille
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A RomeroL Romero Acuña
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FumoleauM T Closon
Jan 1, 1996·Breast Cancer Research and Treatment·M TerenzianiG Bonadonna
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·B FazenyC Dittrich
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B LivingstonC A Long
Jun 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C VogelC McGuirt
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D I UdomR C Coombes
Dec 18, 2001·Cancer·L ZelekM Spielmann
Jun 3, 2005·Japanese Journal of Clinical Oncology·Masakazu ToiShigemitsu Takashima
Aug 7, 2009·Journal of the National Cancer Institute·Fatima CardosoUNKNOWN ESO-MBC Task Force
Dec 1, 2007·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hai-Rim ShinKeun-Young Yoo
Citations
Sep 25, 2012·The Oncologist·Carlo PalmieriR Charles Coombes
Mar 2, 2016·Breast Cancer Research and Treatment·A WeltS Hegewisch-Becker
Jun 16, 2015·Future Oncology·Guy JerusalemJoëlle Collignon
May 31, 2011·The Lancet Oncology·Linda J M OostendorpPetronella B Ottevanger
Jul 10, 2014·ISRN Oncology·Athina StravodimouIoannis A Voutsadakis
Sep 26, 2012·Onkologie·Lina Pugliano, Evandro de Azambuja
Jul 18, 2015·PloS One·Ting LiXichun Hu
Feb 7, 2012·Cancer Chemotherapy and Pharmacology·Ningning DongQisen Guo
Dec 15, 2020·Journal of Oncology·Vito LorussoFrancesco Giotta